Moneycontrol PRO

Buy Gland Pharma: target of Rs 4400: Sharekhan

Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4400 in its research report dated September 29, 2021.

September 30, 2021 / 01:13 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Gland Pharma

Well diversified product portfolio, strong product pipeline would drive the Core markets performance, while expanding geographic footprint with plans to enter China bodes well from growth perspective. Opportunities from Sputnik Vaccine, and plans to enter the biosimilar CDMO space would be key growth driver for Gland. Gland has lined up a Rs 770 crore capex over FY22E-FY23E, which could enable it to cater to increased demand for existing as well as new products.


We re-iterate Buy recommendation on Gland Pharma (Gland) with unchanged PT of Rs 4400. Stock price correction of ~14% from its highs provides a good entry point for investors.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Sep 30, 2021 01:13 pm
ISO 27001 - BSI Assurance Mark